A Fatal Case of Immune Checkpoint Inhibitor‐Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma

Documenti analoghi

• Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept
  di: Zeinab Alnahas, et al.
  Pubblicazione: (2026)
• A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
  di: Matthew Youssef, et al.
  Pubblicazione: (2026)
• Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate
  di: Lena Huber, et al.
  Pubblicazione: (2025)
• Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF ‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF / MEK Inhibitors: A Case Report
  di: Akira Shibata, et al.
  Pubblicazione: (2026)
• Successful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report
  di: Takahiro Sasaki, et al.
  Pubblicazione: (2025)